Research update for articles published in EJCI in 2010

European Journal of Clinical Investigation

Volumn 42, Issue 11, 2012, Pages 1149-1164

  Adlbrecht, Christopher ^a   Aigner, Elmar ^b   Bellón, Juan M ^c,d   Bouloukaki, Izolde ^e   Bouzas Mosquera, Alberto ^f   Carrilho, Alexandre J F ^g   Chang, Kuo Chu ^h   Chattipakorn, Nipon ⁱ   Chattipakorn, Siriporn C ⁱ   Chen, Yi Jen ^j,k   Chung, Yuan Chiang ^l   Colah, Roshan ^m   Datz, Christian ^a   Frøkjær, Jens B ⁿ   Fujimori, Shunji ^o   Georgiadou, Panagiota ^p   Grion, Cintia M ^g   Hsu, Chih Ping ^q   Hülsmann, Martin ^a   Hung, Ming Jui ^r   Hung, Ming Yow ^j,s   Iliodromitis, Efstathios K ^t   Lang, Irene M ^a   Lee, Ting I ^j,k   März, Winfried ^u,v,w   Nair, Sona B ^m   Pascual, Gemma ^c,d   Peteiro, Jesús ^f   Sakamoto, Choitsu ^o   Satomura, Atsushi ^x   Schiza, Sophia E ^e   Stärkel, Peter ^y,z   Stojakovic, Tatjana ^u   Vesely, David L ^aa,ab   Walters, Darren L ^ac   Yilmaz, Yusuf ^ad,ae   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^e UNIVERSITY OF CRETE   (Greece)

^f UNIVERSITY OF A CORUÑA   (Spain)

^g STATE UNIVERSITY OF LONDRINA   (Brazil)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ CHIANG MAI UNIVERSITY   (Thailand)

^j School of Medicine   (Taiwan)

^k TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^l CHENG CHING GENERAL HOSPITAL   (Taiwan)

^m NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

ⁿ AALBORG UNIVERSITY HOSPITAL   (Denmark)

^o NIPPON MEDICAL SCHOOL   (Japan)

^p ONASSIS CARDIAC SURGERY CENTER   (Greece)

^q YUANPEI UNIVERSITY   (Taiwan)

^r CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^s TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^t NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^u MEDICAL UNIVERSITY OF GRAZ   (Austria)

^v UNIVERSITY OF HEIDELBERG   (Germany)

^w SYNLAB ACADEMY   (Germany)

^x NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^y UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^z CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^aa VETERANS AFFAIRS MEDICAL CENTER   (United States)

^ab UNIVERSITY OF SOUTH FLORIDA   (United States)

^ac UNIVERSITY OF QUEENSLAND   (Australia)

^ad Institute of Gastroenterology   (Turkey)

^ae MARMARA UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBULIN; AMINOTRANSFERASE; C REACTIVE PROTEIN; CARDIAC HORMONE; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOKINE; DICLOFENAC; ENOXAPARIN; EPIDERMAL GROWTH FACTOR; EZETIMIBE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR 21; FLUINDOSTATIN; GELATINASE A; HEPARIN; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; LIPOPROTEIN; MANNOSE BINDING LECTIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOMER; OMEPRAZOLE; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTON PUMP INHIBITOR; RAS PROTEIN; SIMVASTATIN; TIROFIBAN; UNCLASSIFIED DRUG; UROCORTIN;

ACUTE HEART INFARCTION; ALCOHOL LIVER DISEASE; ARTICLE; BLEEDING; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC KIDNEY FAILURE; CORONARY ARTERY SPASM; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG MECHANISM; DRUG MEGADOSE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEMOGLOBINOPATHY; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INGUINAL HERNIA; INTESTINE INJURY; IRON STORAGE; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SEPSIS; THROMBECTOMY;

EID: 84867748329     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12001     Document Type: Article

References (103)

1. Stojakovic T, de Campo A, Scharnagl H, Sourij H, Schmölzer I, Wascher TC et al. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest 2010;40:187-94.
2. Winkler K, Jacob S, Muller-Schewe T, Hoffmann MM, Konrad T. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 2012;220:189-93.
3. Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin 2011;27:685-92.
4. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010;31:1633-9.
5. Bays H, Conard S, Leiter LA, Bird S, Jensen E, Hanson ME et al. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis 2010;9:136.
6. Nair S, Nadkarni A, Warang P, Bhave A, Ghosh K, Colah R. Five alpha globin chain variants identified during screening for haemoglobinopathies. Eur J Clin Invest 2010;40:226-32.
7. Upadhye DS, Jain D, Nair SB, Nadkarni AH, Ghosh K, Colah RB. First case of Hb Fontainebleau with sickle hemoglobin and other non-deletional α gene variants identified in neonates during newborn screening for sickle cell disorders. J Clin Pathol 2012;65:654-9.
8. Chopra A, Fisher C, Khunger JM, Pati H. Hemoglobin O (Indonesia) in India: a rare observation. Ann Hematol 2011;90:353-4.
9. Sharma A, Marwah S, Buxi G, Yadav RB. Falsely low HbA1c value due to rare hemoglobin variant (Hemoglobin J Meerut) - A family study. Indian J Pathol Microbiol 2012;55:270-1.
10. Warang P, Nair S, Nadkarni A, Ghosh K, Colah RB. HbH disease due to homozygosity for a rare α2 globin variant, Hb Sallanches. Hemoglobin 2010;34:45-8.
11. Nadkarni AH, Nair SB, Italia KY, Warang P, Dalvi M, Ghosh K et al. Molecular diversity of hemoglobin H disease in India. Am J Clin Pathol 2010;133:491-4.
12. Sun Y, Eichelbaum EJ, Lenz A, Wang H, Vesely DL. Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones. Eur J Clin Invest 2010;40:408-13.
13. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H et al. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009;29:971-5.
14. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV, Wang H, Vesely DL. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009;29:1889-93.
15. Sun Y, Eichelbaum EJ, Lenz A, Wang H, Vesely DL. Four cardiac hormones inhibit insulin's mitogenic action via inhibiting Ras. Cancer Ther 2009;7:367-72.
16. McGrath ME, Ogawa T, de Bold AJ. Ras dexamethasone-induced protein 1 is a modulator of hormone secretion in volume overloaded heart. Am J Physiol Heart Circ Physiol 2012;302:H1826-7.
17. Lenz A, Sun Y, Eichelbaum EJ, Skelton WP IV, Pi G, Vesely DL. Cardiovascular hormones eliminate some human squamous cell lung carcinomas in athymic mice. Eur J Clin Invest 2010;40:242-9.
18. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr, Vesely DL. Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 2008;38:562-70.
19. Fujimori S, Gudis K, Takahashi Y, Seo T, Yamada Y, Ehara A et al. Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest 2010;40:504-10.
20. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314-22.
21. Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review. Methods Mol Biol 2004;268:491-502.
22. Adlbrecht C, Distelmaier K, Bonderman D, Beran G, Redwan B, Strunk G et al. Long-term outcome after thrombectomy in acute myocardial infarction. Eur J Clin Invest 2010;40:233-41.
23. Adlbrecht C, Distelmaier K, Gunduz D, Redwan B, Plass C, Bonderman D et al. Target vessel reopening by guidewire insertion in ST-elevation myocardial infarction is a predictor of final TIMI flow and survival. Thromb Haemost 2011;105:52-8.
24. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ et al. Cardiac death and reinfarction after 1year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008;371:1915-20.
25. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55.
26. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012;307:1817-26.
27. Georgiadou P, Iliodromitis EK, Kolokathis F, Varounis C, Gizas V, Mavroidis M et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest 2010;40:288-93.
28. Mazzone A, Parri MS, Giannessi D, Ravani M, Vaghetti M, Altieri P et al. Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study. Coron Artery Dis 2011;22:179-87.
29. de Kleijn DP, Moll FL, Hellings WE, Ozsarlak-Sozer G, de Bruin P, Doevendans PA et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 2010;30:612-9.
30. Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S, Zaromitidou M et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2012; May 26. In press.
31. Momiyama Y, Ohmori R, Fayad ZA, Kihara T, Tanaka N, Kato R et al. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis 2010;210:668-70.
32. Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2010;9:70.
33. Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK et al. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest 2010;40:330-8.
34. Hara T, Ishida T, Kojima Y, Tanaka H, Yasuda T, Shinohara M et al. Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo. J Lipid Res 2011;52:57-67.
35. Henning MF, Herlax V, Bakás L. Contribution of the C-terminal and of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect. Innate Immun 2011;17:327-37.
36. Walters DL, Ray MJ, Wood P, Perrin EJ, Bett JH, Aroney CN. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention. Eur J Clin Invest 2010;40:139-47.
37. Layland J, Ray MJ, Siresena T, Walters DL. Increased expression of monocyte tissue factor and soluble CD40 ligand at mid-term follow-up following percutaneous coronary intervention. Blood Coagul Fibrinolysis 2011;22:349-50.
38. Ray MJ, Calabro LJ, Sirisena T, Crawford SA, Crawford RW, Walters DL. Pre-operative platelet-bound CD40 ligand is probably associated with peri-operative cardiac events in hip and knee arthroplasty. Eur J Clin Invest 2010;40:497-503.
39. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011;4:654-64.
40. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
41. Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
42. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010;40:887-92.
43. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010;53:934-40.
44. Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS ONE 2011;6:e24895.
45. Adlbrecht C, Hülsmann M, Gwechenberger M, Graf S, Wiesbauer F, Strunk G et al. Electrical optimization of cardiac resynchronization in chronic heart failure is associated with improved clinical long-term outcome. Eur J Clin Invest 2010;40:678-84.
46. Adlbrecht C, Hülsmann M, Gwechenberger M, Strunk G, Khazen C, Wiesbauer F et al. Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment. Eur J Clin Invest 2009;39:1073-81.
47. Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S, Waggoner AD et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010;122:2660-8.
48. Shanmugam N, Borgulya G, Anderson L. Letter by Shanmugam et al. regarding article, "Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy". Circulation 2011;124:e190.
49. Sawhney NS, Waggoner AD, Garhwal S, Chawla MK, Osborn J, Faddis MN. Randomized prospective trial of atrioventricular delay programming for cardiac resynchronization therapy. Heart Rhythm 2004;1:562-7.
50. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
51. Bouzas-Mosquera A, Peteiro J, Broullón FJ, Álvarez-García N, Méndez E, Pérez A et al. Value of exercise echocardiography for predicting mortality in elderly patients. Eur J Clin Invest 2010;40:1122-30.
52. Peteiro J, Bouzas-Mosquera A, Estevez R, Pazos P, Piñeiro M, Castro-Beiras A. Head-to-head comparison of peak supine bicycle exercise echocardiography and treadmill exercise echocardiography at peak and at post-exercise for the detection of coronary artery disease. J Am Soc Echocardiogr 2012;25:319-26.
53. Bernheim AM, Kittipovanonth M, Takahashi PY, Gharacholou SM, Scott CG, Pellikka PA. Does the prognostic value of dobutamine stress echocardiography differ among different age groups? Am Heart J 2012;25:319-5.
54. Rai M, Baker WL, Parker MW, Heller GV. Meta-Analysis of Optimal Risk Stratification in Patients >65 Years of Age. Am J Cardiol 2012; Jul 12. In press.
55. Schiza SE, Mermigkis C, Panagiotis P, Bouloukaki I, Kallergis E, Tzanakis N et al. C-reactive protein evolution in obstructive sleep apnoea patients under CPAP therapy. Eur J Clin Invest 2010;40:968-75.
56. Guo Y, Pan L, Ren D, Xie X. Impact of continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2012; Jun 5. In Press.
57. Mermigkis C, Bouloukaki I, Mermigkis D, Kallergis E, Mavroudi E, Varouchakis G et al. CRP evolution pattern in CPAP-treated obstructive sleep apnea patients. Does gender play a role. Sleep Breath 2011;16:1-3.
58. Kumor M, Bielicki P, Przybylowski T, Rubinsztajn R, Zieliński J, Chazan R. Three month continuous positive airway pressure (CPAP) therapy decreases serum total and LDL cholesterol, but not homocysteine and leptin concentration in patients with obstructive sleep apnea syndrome (OSAS)]. Pneumonol Alergol Pol 2011;79:173-83.
59. Colish J, Walker JR, Elmayergi N, Almutairi S, Alharbi F, Lytwyn M et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest 2012;141:674-81.
60. Chang KC, Tseng CD, Lu SC, Liang JT, Wu MS, Tsai MS et al. Effects of acetyl-L-carnitine and oxifenicine on aorta stiffness in diabetic rats. Eur J Clin Invest 2010;40:1002-10.
61. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000;43:550-7.
62. Satomura A, Fujita T, Fuke Y, Yanai M, Kumasaka K, Takayama E et al. Relationship between oligomer and functional serum mannose-binding lectin in chronic renal failure. Eur J Clin Invest 2010;40:865-73.
63. Satomura A, Fujita T, Yanai M, Kumasaka K, Uehara Y, Okada K et al. Functional mannose-binding lectin levels in patients with end-stage renal disease on maintenance hemodialysis. J Innate Immun 2012;4:293-300.
64. Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995;345:886-9.
65. Frøkjær JB, Søfteland E, Graversen C, Dimcevski G, Drewes AM. Effect of acute hyperglycaemia on sensory processing in diabetic autonomic neuropathy. Eur J Clin Invest 2010;40:883-6.
66. Frøkjær JB, Egsgaard LL, Graversen C, Søfteland E, Dimcevski G, Blauenfeldt RA et al. Gastrointestinal symptoms in type-1 diabetes: Is it all about brain plasticity? Eur J Pain 2011;15:249-57.
67. Frøkjær JB, Andersen LW, Brock C, Simrén M, Ljungberg M, Søfteland E et al. Altered brain microstructure assessed by diffusion tensor imaging in patients with diabetes mellitus and gastrointestinal symptoms. Diabetes Care 2012; In press.
68. Lee TI, Kao YH, Chen YC, Pan NH, Chen YJ. Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart. Eur J Clin Invest 2010;40:692-9.
69. Lee TI, Kao YH, Chen YC, Pan NH, Lin YK, Chen YJ. Cardiac peroxisome-proliferator-activated receptor expression in hypertension co-existing with diabetes. Clin Sci (Lond) 2011;121:305-12.
70. Cheng CC, Pan NH, Chen YC, Yeh HI, Lin CI, Chen SA et al. Atherosclerosis modulates the electrophysiological effects of a peroxisome proliferator-activated receptor-gamma activator on pulmonary veins. Int J Cardiol 2010;145:578-82.
71. Lee TI, Chen YC, Kao YH, Hsiao FC, Lin YK, Chen YJ. Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration. Int J Cardiol 2012; In press.
72. Skelton WP IV, Pi G, Lenz A, Vesely DL. Cardiac hormones inhibit proliferation of pancreatic cancer but not normal cells. Eur J Clin Invest 2010;40:706-12.
73. Serafino A, Moroni N, Psaila R, Zonfrillo M, Andreola F, Wannenes F et al. Anti- proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt- mediated cross-talk between acidic tumor microenvironment and Wnt/β-catenin signaling. Biochim Biophys Acta 2012;1822:1004-18.
74. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL et al. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 2007;21:445-52.
75. Skelton WP IV, Pi GE, Vesely DL. Four cardiac hormones cause death of human cancer cells but not of healthy cells. Anticancer Res 2011;31:395-402.
76. Pi GE, Skelton WP IV, Vesely DL. Four cardiac hormones cause cytotoxicity of human cancer cells but not of healthy cells. Cancer Ther 2011;8:44-50.
77. Chung YC, Lin CC, Chou CC, Hsu CP. The effect of Longan seed polyphenols on colorectal carcinoma cells. Eur J Clin Invest 2010;40:713-21.
78. Chung YC, Lin CC, Hsu CP. The potential roles of longan flower and seed extracts in cancer prevention and treatment. World J Exp Med 2012; (under revision).
79. Stärkel P, De Saeger C, Strain AJ, Leclercq I, Horsmans Y. NFκB, cytokines, TLR 3 and 7 expression in human end-stage HCV and alcoholic liver disease. Eur J Clin Invest 2010;40:575-84.
80. Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M et al. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain Behav Immun 2012;26:911-8.
81. Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, Tanaka T et al. Hepatitis C Virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 2011;204:793-801.
82. Berzsenyi MD, Roberts SK, Preiss S, Woollard DJ, Beard MR, Skinner NA et al. Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF-α in HCV & HCV/HIV infection. J Viral Hepat 2011;18:852-60.
83. Hung MY, Hsu KH, Hung MJ, Cheng CW, Cherng WJ. Interactions among gender, age, hypertension and C-reactive protein in coronary vasospasm. Eur J Clin Invest 2010;40:1094-103.
84. Hung MJ, Cherng WJ, Hung MY, Kuo LT, Cheng CW, Wang CH et al. Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. Atherosclerosis 2012;221:521-6.
85. Wang S, Reed DB, Goli S, Goswami D. Blood leptin and C-reactive protein provide more sensitive assessment than blood lipids and other inflammatory biomarkers in overweight university students. Nutr Res 2011;31:586-93.
86. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S et al. Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. Cardiovasc Diabetol 2011;10:51.
87. Kawano H, Node K. The role of vascular failure in coronary artery spasm. J Cardiol 2011;57:2-7.
88. Pascual G, Rodríguez M, Gómez-Gil V, Trejo C, Buján J, Bellón PG. Active metalloproteinase-2 upregulation in the abdominal skin of patients with direct inguinal hernia. Eur J Clin Invest 2010;40:113-1121.
89. Klinge U, Si ZY, Zheng H, Schumpelick V, Bhardwaj RS, Klosterhalfen B. Abnormal collagen I and III distribution in the skin of patients with incisional hernia. Eur Surg Res 2000;32:43-8.
90. Rosch R, Klinge U, Si Z, Junge K, Klosterhalfen B, Schumpelick V. A role for the collagen I/III and MMP-1/13 genes in primary inguinal hernia? BMC Med Genet 2002;3:2.
91. Bellón JM, Buján J, Honduvilla NG, Jurado F, Gimeno MJ, Turnay J et al. Study of biochemical substrate and role of metalloproteinases in fascia transversalis from hernial processes. Eur J Clin Invest 1997;27:510-6.
92. Bellón JM, Bajo A, Ga-Honduvilla N, Gimeno MJ, Pascual G, Guerrero A et al. Fibroblasts from the transversalis fascia of young patients with direct inguinal hernias show constitutive MMP-2 over-expression. Ann Surg 2001;233:287-91.
93. Antoniou GA, Tentes IK, Antoniou SA, Simopoulos C, Lazarides MK. Matrix metalloproteinase imbalance in inguinal hernia formation. J Invest Surg 2011;24:145-50.
94. Phrommintikul A, Sivasinprasasn S, Lailerd N, Chattipakorn S, Kuanprasert S, Chattipakorn N. Plasma urocortin in acute myocardial infarction patients. Eur J Clin Invest 2010;40:874-82.
95. Calderón-Sánchez EM, Ruiz-Hurtado G, Smani T, Delgado C, Benitah JP, Gómez AM et al. Cardioprotective action of urocortin in postconditioning involves recovery of intracellular calcium handling. Cell Calcium 2011;50:84-90.
96. Takatani-Nakase T, Takahashi K. Cardioprotective activity of urocortin by preventing caspase-independent, non-apoptotic death in cultured neonatal rat cardiomyocytes exposed to ischemia. Biochem Biophys Res Commun 2010;402:216-21.
97. Barry SP, Lawrence KM, McCormick J, Soond SM, Hubank M, Eaton S et al. New targets of urocortin-mediated cardioprotection. J Mol Endocrinol 2010;45:69-85.
98. Aigner E, Hinz C, Steiner K, Rossmann B, Pfleger J, Hohla F et al. Iron stores, liver transaminase levels and metabolic risk in healthy teenagers. Eur J Clin Invest 2010;40:155-63.
99. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77-85.
100. Weismuller TJ, Kirchner GI, Scherer MN, Negm AA, Schnitzbauer AA, Lehner F et al. Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology 2011;54:2114-24.
101. Houschyar KS, Ludtke R, Dobos GJ, Kalus U, Broecker-Preuss M, Rampp T et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med 2012;10:54.
102. Aigner E, Strasser M, Haufe H, Sonnweber T, Hohla F, Stadlmayr A et al. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol 2010;105:1978-85.
103. Aigner E, Felder TK, Oberkofler H, Hahne P, Auer S, Soyal S et al. Glucose acts as a regulator of serum iron by increasing serum hepcidin concentrations. J Nutr Biochem 2012.